Literature DB >> 16943529

Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.

Jean Klastersky1, Marianne Paesmans, Aspasia Georgala, Frédérique Muanza, Barbara Plehiers, Laurent Dubreucq, Yassine Lalami, Michel Aoun, Martine Barette.   

Abstract

PURPOSE: Since febrile neutropenic patients were recognized to constitute a heterogeneous population, several models have been developed for predicting the risk of serious medical complications. The Multinational Association for Supportive Care in Cancer score and its derived clinical prediction rules have been validated, but thus far there were no data about its use for simplifying therapy in predicted low-risk patients. PATIENTS AND METHODS: In a single institution, we followed all episodes of febrile neutropenia between January 1999 and November 2003. Those patients predicted at low risk for complications, who were not receiving antibacterials at fever onset and were eligible for treatment with oral antibiotics, were treated with ciprofloxacin and amoxicillin-clavulanate and were discharged if they were clinically stable or improving after an initial observation period. The primary end point of the study was the rate of resolution of the febrile neutropenic episode without complications, among these early discharged patients.
RESULTS: Of 383 first febrile neutropenic episodes predicted at low risk of complication, 178 patients (33 men and 145 women, mainly with solid tumors) were treated orally; they constituted the basis of our analysis. Seventy-nine patients (44%) were discharged early (with a median time to discharge of 26 hours); no complications occurred among them but three patients had to be readmitted, resulting in a success rate of 96% (95% CI, 92% to 100%).
CONCLUSION: Our study shows that oral therapy followed by early discharge was feasible in a small but significant proportion of patients selected by a strategy combining predicted low risk and medical and nonmedical criteria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943529     DOI: 10.1200/JCO.2005.03.9909

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  49 in total

1.  Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial.

Authors:  James A Talcott; Beow Y Yeap; Jack A Clark; Robert D Siegel; Elizabeth Trice Loggers; Charles Lu; Paul A Godley
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

2.  Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial.

Authors:  Ann M Hendricks; Elizabeth Trice Loggers; James A Talcott
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

Review 3.  Febrile neutropenia in hematologic malignancies.

Authors:  Michael K Keng; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

4.  The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas.

Authors:  Xiao Jun Wang; Denise Yun Ting Goh; Sreemanee Raaj Dorajoo; Alexandre Chan
Journal:  Support Care Cancer       Date:  2017-04-11       Impact factor: 3.603

5.  A new prognostic model for chemotherapy-induced febrile neutropenia.

Authors:  Shin Ahn; Yoon-Seon Lee; Jae-Lyun Lee; Kyung Soo Lim; Sung-Cheol Yoon
Journal:  Int J Clin Oncol       Date:  2015-06-07       Impact factor: 3.402

6.  Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score as a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors.

Authors:  Roger A Bitar
Journal:  Perm J       Date:  2015

Review 7.  Rapid Fire: Infectious Disease Emergencies in Patients with Cancer.

Authors:  Stephanie Charshafian; Stephen Y Liang
Journal:  Emerg Med Clin North Am       Date:  2018-06-11       Impact factor: 2.264

8.  Direct costs associated with febrile neutropenia in inpatients with hematological diseases in Singapore.

Authors:  Yvonne Peijun Zhou; Jing Jin; Ying Ding; Yen Lin Chee; Liang Piu Koh; Wee Joo Chng; Douglas Su-Gin Chan; Li Yang Hsu
Journal:  Support Care Cancer       Date:  2013-11-28       Impact factor: 3.603

9.  A cohort study on protocol-based nurse-led out-patient management of post-chemotherapy low-risk febrile neutropenia.

Authors:  Fiona Lim Mei Ying; Maria Choy Yin Ping; Macy Tong; Elaine Yim Pik Yan; Tracy Lui Siu Yee; Lam Yuk Ting; Anita Lo Wing Sim; Lui Cheuk Yu; Bosco Lam Hoi Shiu; Ashley Cheng Chi Kin
Journal:  Support Care Cancer       Date:  2018-03-20       Impact factor: 3.603

10.  The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia.

Authors:  Jean Klastersky; Harry Raftopoulos; Bernardo Rapoport
Journal:  Support Care Cancer       Date:  2013-03-24       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.